Does preoperative clopidogrel increase bleeding after coronary bypass surgery?

Area of Science:

• Cardiology
• Cardiovascular Surgery
• Pharmacology

Background:

• Antiplatelet therapy, like clopidogrel, reduces cardiac events in acute coronary syndrome.
• However, these therapies increase bleeding risk, posing challenges for patients needing surgery.

Purpose of the Study:

• To evaluate if clopidogrel use within 5 days of coronary artery bypass grafting (CABG) impacts bleeding outcomes.
• To compare transfusion requirements in patients with different clopidogrel cessation timings before CABG.

Main Methods:

• A study of 342 patients undergoing elective on-pump CABG between 2004 and 2008.
• Patients were divided into two groups: clopidogrel stopped >5 days before surgery (n=191) and ≤5 days before surgery (n=151).
• Bleeding outcomes (drainage at 8h, 12h, and total) and blood product transfusion needs were assessed.

Main Results:

• No significant differences in postoperative drainage were observed between the groups.
• Blood product usage was similar for patients who stopped clopidogrel >5 days earlier versus ≤5 days before surgery.
• No instances of reoperation for hemostasis occurred in either group.

Conclusions:

• Preoperative clopidogrel exposure, even within 5 days of surgery, does not elevate the risk of bleeding complications or transfusion needs during CABG.
• Current guidelines on clopidogrel cessation before CABG may not be necessary to prevent hemostatic complications.